NASDAQ · RGC
Regencell Bioscience Holdings Limited financials
$6.200.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$3.8M | -$4.7M | -$6.3M | -$7.6M |
| Net income | -$3.6M | -$4.3M | -$6.1M | -$7.4M |
| Net margin | — | — | — | — |
| Diluted EPS | $-0.01 | $-0.01 | $-0.01 | $-0.02 |
| EBITDA | -$3.7M | -$4.4M | -$6.0M | -$7.0M |
| Operating cash flow | -$3.1M | -$4.0M | -$5.0M | -$5.3M |
| Free cash flow | -$3.3M | -$4.0M | -$5.0M | -$6.0M |
| Diluted shares | 494.5M | 494.5M | 494.5M | 486.6M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|
| Cash & equivalents | $2.4M | $3.0M | $1.6M | $6.4M |
| Short-term investments | $2.5M | $5.0M | $10.0M | $10.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $5.8M | $8.4M | $12.6M | $18.0M |
| Total liabilities | $895.3K | $219.5K | $632.3K | $938.0K |
| Shareholders' equity | $4.9M | $8.2M | $12.0M | $17.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology